Gastrointestinal Special Issue

Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

Research into treatments for cholangiocarcinoma is branching out, but there are still more questions than answers.

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.

Identified only a decade-and-a-half ago, GIST is already treatable with several targeted therapies, and scientists are researching more.

Scientists are investigating a host of new treatment types that may change the outlook for those with pancreatic cancer.

Diagnoses in younger people and two causative infections are providing clues about how to better prevent and treat gastric cancer.

The decision to remove one's stomach may be difficult, but it can also be life-saving.

When it comes to gastrointestinal (GI) cancers, there’s quite a disparity in the gains that research is bringing us.